IM Therapeutics gets SBIR grant

BROOMFIELD — ImmunoMolecular Therapeutics LLC, or IM Therapeutics, a company developing small molecular therapies for patients with genetically defined autoimmune diseases, has been awarded a grant from the Small Business Innovation Research program.

The Broomfield-based company received the grant for its development of an oral small molecular drug for the preservation of residual beta cell function in type 1 diabetes. The treatment also got Rare Pediatric Disease designation from the U.S. Food and Drug Administration, which can help fast-track the process. The treatment is called D enantiomer of methyldopa, or D-MDOPA.

“The Rare Pediatric Disease designation and SBIR grant awarded to IM Therapeutics for D-MDOPA show the need for new treatment options for type 1 diabetes, a lifelong disease for which there are no approved therapies to treat the underlying autoimmunity,” Aaron Michels, chief scientific officer for IM Therapeutics, said in a prepared statement. The goal is to help maintain normal insulin production.

SPONSORED CONTENT

Business Cares: April 2024

In Colorado, 1 in 3 women, 1 in 3 men and 1 in 2 transgender individuals will experience an attempted or completed sexual assault in their lifetime. During April, we recognize Sexual Assault Awareness Month with the hopes of increasing conversations about this very important issue.

The SBIR grant will help support the development of the treatment and phase 1 studies. The grant amount was not disclosed.